drugset / Trial / NCT00732615

Use of NPSP558 in the Treatment of Hypoparathyroidism

NCT00732615

Phase 3 Completed 124 enrolled Shire
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Use of PTH (1-84) a recombinant hormone in escalating doses for the treatment of adults with hypoparathyroidism. The use of PTH should result in a decrease of calcium and vitamin D supplements.

Timeline

Start
2008-12-18
Primary completion
2011-09-28
Completion
2011-09-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Parathyroid Hormone Protein / enzyme biologic 100 ug Subcutaneous

Indications